| Literature DB >> 30655706 |
Greg Ridgeway1,2,3, Mette Nørgaard4, Thomas Bøjer Rasmussen4, William D Finkle3, Lars Pedersen4, Hans Erik Bøtker5, Henrik Toft Sørensen4.
Abstract
OBJECTIVE: The aim of this study was to examine hospital performance measures that account more comprehensively for unique mixes of patients' characteristics.Entities:
Keywords: case mix adjustment; cohort study; doubly robust estimation; performance measurement; propensity score
Year: 2019 PMID: 30655706 PMCID: PMC6324920 DOI: 10.2147/CLEP.S189263
Source DB: PubMed Journal: Clin Epidemiol ISSN: 1179-1349 Impact factor: 4.790
Distribution of selected characteristics in an index hospital population (Hospital Z), its benchmark population, and all patients at other hospitals in Denmark
| Patient features | Index Hospital Z | Benchmark patients | All other hospitals |
|---|---|---|---|
| Basic demographics, % | |||
| Age, average | 69.9 | 69.9 | 68.6 |
| Male | 55.7 | 55.2 | 57.4 |
| Primary cardiovascular discharge diagnosis at index admission, % | |||
| Acute coronary syndrome (any), I20, I21, I25.1, and I25.9 | 24.4 | 24.5 | 22.0 |
| Myocardial infarction (any), I21 | 8.8 | 8.9 | 10.5 |
| ST elevation myocardial infarction, I21.0B, I21.1B, and I21.3 | 0.5 | 0.5 | 3.1 |
| Non-ST elevation myocardial infarction, I21.0A, I21.1A, and I21.4 | 5.0 | 5.1 | 4.7 |
| Acute myocardial infarction (unspecified), I21, excluding I21.0A, I21.1A, I21.4, I21.0B, I21.1B, and I21.3 | 3.3 | 3.3 | 2.8 |
| Unstable angina, I20.0 | 4.2 | 4.2 | 2.4 |
| Stable coronary artery disease, I20, I25.1, and I25.9 | 15.7 | 15.7 | 11.4 |
| Stable angina pectoris, I20 (except I20.0), I25.1, and I25.9 | 11.5 | 11.5 | 9.1 |
| Chronic ischemic heart disease (unspecified), I25.9 | 2.2 | 2.2 | 2.7 |
| Heart failure, first time admission, I50, I11.0, I13.0, I13.2, I42.0, I42.6, I42.7, I42.8, and I42.9 | 9.3 | 9.3 | 9.2 |
| Arterial hypertension, I10–I15 | 8.2 | 8.2 | 5.4 |
| Atrial fibrillation or flutter, I48 | 27.7 | 27.9 | 23.8 |
| Bradycardia, I48, I44.0–I44.3, I45.5A, I45.5B, I45.5C, and I45.5G | 28.5 | 28.7 | 25.3 |
| Ventricular tachycardia, I47.0, I47.2, and I49.0 | 0.5 | 0.5 | 0.9 |
| Valvular heart disease, I05, I34, I39.0, I51.1A, I06, I35, and I39.1 | 1.1 | 1.1 | 2.2 |
| Stroke (any), I60–64 | 5.8 | 5.8 | 13.1 |
| Ischemic stroke, I63–I64 | 4.7 | 4.7 | 11.4 |
| Hemorrhagic stroke, I60–61 | 1.2 | 1.1 | 1.7 |
| Stroke, unspecified, I64 | 1.3 | 1.3 | 2.2 |
| Selected cardiovascular diagnosis history (look back period: 5 years), % | |||
| Ischemic heart disease, I20–I25 | 25.2 | 25.5 | 26.8 |
| Myocardial infarction, I21 | 9.3 | 9.1 | 9.4 |
| Angina pectoris, I20, I25.1, and I25.9 | 21.5 | 21.9 | 23.6 |
| Heart failure, I50, I11.0, I13.0, I13.2, I42.0, I42.6, I42.7, I42.8, and I42.9 | 11.2 | 11.6 | 16.0 |
| Cardiomyopathy, I42 | 2.7 | 2.4 | 3.1 |
| Arterial hypertension, I10–I15 | 27.8 | 28.3 | 33.0 |
| Cardiac arrhythmias (any), I48, I44.0-I44.3, I45.5A,B,C,G, I47.0, I47.2, I49.0, and I46 | 30.3 | 30.4 | 30.6 |
| Atrial fibrillation or flutter, I48, I44.0, I44.1, I44.2, I44.3, and I45.5A,B,C,G | 29.3 | 29.6 | 29.4 |
| Ventricular tachycardia or fibrillation, I47.0, I47.2, and I49.0 | 1.4 | 1.5 | 2.3 |
| Valvular heart disease, I05, I34, I39.0, I51.1A, I06, I35, and I39.1 | 5.0 | 5.2 | 8.1 |
| Stroke (any), I60–I64 | 7.0 | 7.1 | 8.3 |
| Ischemic stroke, I63–I64 | 6.6 | 6.7 | 7.7 |
| Hemorrhagic stroke, I60–61 | 0.5 | 0.6 | 0.9 |
| Current | |||
| Nitrates, C01DA | 16.1 | 15.8 | 11.0 |
| Antiplatelets, B01AC | 40.6 | 40.0 | 36.7 |
| Anticoagulants, B01AA03, B01AA04, B01AB, B04AX04, B01AE, B01AX02, B01AX03, B01AF, and B01AX, excluding B01AX02, B01AX03, and B01AX06 | 24.5 | 24.0 | 22.9 |
| Beta blockers, C07 | 44.3 | 44.1 | 40.9 |
| ACE inhibitors, C09AA and C02EA | 27.1 | 26.6 | 22.3 |
| Angiotensin II receptor blockers, C09CA andC02EX01 | 12.5 | 12.1 | 12.1 |
| Calcium channel blockers, C08 | 25.4 | 25.7 | 23.7 |
| Diuretics, C03 and C02DF01 | 44.2 | 43.6 | 37.5 |
| Digoxin, C01AA | 10.7 | 10.4 | 8.2 |
| Amiodarone, C01BD01 | 2.9 | 2.7 | 3.1 |
| Lipid lowering drugs C10A | 40.5 | 40.5 | 38.8 |
| Previous cardiac procedures (look back period: 5 years), % | |||
| Percutaneous coronary intervention (any) | 6.8 | 7.2 | 7.7 |
| Coronary artery bypass grafting | 2.0 | 1.9 | 2.3 |
| Cardiac resynchronization therapy | 5.5 | 5.8 | 7.5 |
| Radiofrequency ablation | 3.2 | 3.4 | 3.9 |
| Cardiac pacemaker | 5.0 | 4.7 | 5.0 |
| Implantable cardiac defibrillator | 1.4 | 1.4 | 2.0 |
| Mitral valve surgery | 0.2 | 0.3 | 0.7 |
| Aortic valve surgery | 1.1 | 1.0 | 1.6 |
| Selected comorbidity diagnosis history (look back period: 5 years), % | |||
| Diabetes | 11.1 | 11.4 | 12.9 |
| COPD | 9.7 | 9.4 | 9.0 |
| Renal disease | 3.5 | 3.7 | 5.6 |
| Liver disease | 0.8 | 0.8 | 1.5 |
| Venous thromboembolism | 3.8 | 3.9 | 4.4 |
| Connective tissue disease | 2.8 | 3.0 | 3.3 |
| Cancer (any except NMSC) | 9.7 | 9.4 | 9.1 |
| Dementia | 1.1 | 1.2 | 1.8 |
| Current | |||
| Antidepressants, N06A | 9.8 | 9.4 | 7.9 |
| Selective serotonin reuptake inhibitors, N06AB | 12.0 | 11.6 | 9.6 |
| Antipsychotics, N05A | 4.8 | 4.5 | 3.6 |
| Opioids, N02A | 21.0 | 20.6 | 18.6 |
| NSAIDs, M01A, excluding M01AX | 15.9 | 15.7 | 14.4 |
| Aspirin, high-dose N02BA01, and N02BA51 | 2.6 | 2.6 | 1.9 |
| Paracetamol, N02BE | 28.6 | 28.2 | 24.1 |
| Systemic glucocorticoids, H02AB | 9.0 | 8.9 | 8.0 |
| Antidiabetics, A10 | 13.5 | 13.8 | 14.1 |
| Disease-modifying anti-rheumatic drugs, M01C | 0.0 | 0.0 | 0.0 |
| Antibiotics, J01 | 34.7 | 34.1 | 33.3 |
| Anti-ulcer drugs, A02B | 28.6 | 28.0 | 26.1 |
| Drugs used in alcohol dependence, N07BB | 0.4 | 0.5 | 0.5 |
Notes: For primary cardiovascular discharge diagnosis at index admission, the model also matched on 105 specific ICD-10 codes, but we aggregate them here to show the results more compactly. Except for age, which is presented as the average age, all other figures are percentages.
Defined as at least one prescription within 6 months before admission.
Abbreviations: ACE, angiotensin-converting enzyme; NMSC, non-melanoma skin cancer.
Figure 1Comparison of the age distribution of Hospital Z (black) to the age distribution of Hospital Z’s benchmark population of patients (red).
Notes: (A) Comparison of the distribution for all patients. (B) The age distribution also matches within (arbitrarily selected) I20.0 patients on statins, demonstrating the balance of patients’ features in three-way interactions.
Figure 2Mortality within 30 days of admission by hospital (black) compared with its benchmark population (red).
Notes: Lines connect hospitals to their benchmark population when the false discovery rate exceeds 5%. The numbers above the dots indicate the number needed to harm for hospitals exceeding their benchmark, which are flagged as outliers. The horizontal line is the average mortality rate (5.4%).
Figure 3Readmission within 30 days of discharge by hospital (black) compared to its benchmark population (red).
Notes: Lines connect hospitals to their benchmark population when the false discovery rate exceeds 5%. Numbers above the dots indicate the number needed to harm for hospitals exceeding their benchmark, which are flagged as outliers. The horizontal line marks the average 30-day readmission rate (18.5%).
Comparison of 30-day mortality outliers flagged with benchmarking, unadjusted comparisons, and regression-adjusted comparisons
| Unadjusted comparison flagged… | ||||
|---|---|---|---|---|
| Positive outlier | Negative outlier | Non-outlier | ||
| Benchmarking flagged… | Positive outlier | 4 | 0 | 1 |
| Negative outlier | 1 | 2 | 2 | |
| Non-outlier | 3 | 3 | 10 | |
| Benchmarking flagged… | Positive outlier | 4 | 0 | 1 |
| Negative outlier | 2 | 3 | 0 | |
| Non-outlier | 3 | 8 | 5 | |
Selected hospitals for which benchmarking, unadjusted comparisons, and regression adjustment disagree, including their status as an outlier for 30-day mortality rate
| Hospital ID | Benchmarking, false discovery rate ( | ||
|---|---|---|---|
| Unadjusted | Regression adjusted | ||
| C | 0.000 | 0.209 | 0.000 |
| B | 0.000 | 1.000 | 1.000 |
| A | 0.000 | 0.875 | 1.000 |
| E | 0.002 | 1.000 | 1.000 |
| V | 0.022 | 0.043 | 0.629 |
| X | 0.092 | 0.000 | 0.000 |
| S | 0.189 | 0.150 | 0.023 |
| K | 0.439 | 0.000 | 0.000 |
| Q | 1.000 | 0.053 | 0.325 |
| N | 1.000 | 0.000 | 0.041 |